Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Children With Juvenile Myelomonocytic Leukemia
Year: 2025
Type: article
Abstract: transplant.One NRAS-mutated patient only received 6 courses of azacitidine and had resolution of disease without HSCT.Overall survival in 10 patients, with a median FU time of 3yr9mo since diagnosis and 3yr3mo after first HSCT (n=9) is 90%.(Two patients are within 1 year from first or second HSCT and one is prior to first HSCT and thus outcome cannot yet be reported).Conclusions: Overall survival in the Dutch cohort is excellent.Three of four patients with relapse after first transplant and more than 1yr after a second (or third) transplant are disease free.
Source: EJC Paediatric Oncology
Authors: Anita Frisanco Oliveira, Rafaela Ferreira, Luiz Fernando Mantovani, Angela Venancio, Rafael Balceiro, Luiz Fernando Lopes, Neysimelia Villela
Institution: Hospital de Câncer de Barretos
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4415903306
FWCI:
Cites:
Cited by:
Related to: